ArticleHealth science reports2026
Efficacy and Safety of Butylphthalide for Neurological Recovery After Cardiac Arrest: A Pilot Randomized Controlled Trial.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and Safety of Butylphthalide for Neurological Recovery After Cardiac Arrest: A Pilot Randomized Controlled Trial.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Butylphthalide (NBP) is a neuroprotective agent that ameliorates cerebral ischemia-hypoxia and reperfusion injury. However, evidence regarding whether NBP can improve neurological prognosis in patients with cardiac arrest (CA) remains limited. The present study aims to evaluate the efficacy and safety of butylphthalide treatment in improving neurological function in patients with cardiac arrest. Methods: This research constituted a single-center, randomized, double-blind, placebo-controlled trial. Those meeting the inclusion criteria were randomly allocated to either the NBP group or the Placebo group at a 1:1 ratio. The primary outcome was the proportion of patients with a Cerebral Performance Category (CPC) score of 1 or 2 in each group at 90 days after randomization. Results: A total of 70 patients were included in the final analysis, of whom 34 were in the placebo group and 36 in the NBP group. No statistically significant differences were observed in baseline characteristics between the two groups ( Conclusion: Although butylphthalide treatment significantly reduced levels of brain injury biomarkers in patients with cardiac arrest, it did not significantly improve their 90-day neurological prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.